Commission Directive 2009/9/EC of 10 February 2009 amending Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to medicinal products for veterinary use (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This is the original version (as it was originally adopted).
Wherever possible, particulars shall be given of the results of:
tests demonstrating pharmacological actions;
tests demonstrating the pharmacodynamic mechanisms underlying the therapeutic effect;
tests demonstrating the main pharmacokinetic profile;
tests demonstrating target animal safety;
tests investigating resistance.
Should unexpected results occur during the course of the tests, these should be detailed.
Additionally, the following particulars shall be provided in all pre-clinical studies:
a summary;
a detailed experimental protocol giving a description of the methods, apparatus and materials used, details such as species, age, weight, sex, number, breed or strain of animals, identification of animals, dose, route and schedule of administration;
a statistical analysis of the results, where relevant;
an objective discussion of the results obtained, leading to conclusions on the efficacy and safety of the veterinary medicinal product.
Total or partial omission of any of these data shall be justified.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
